Baseline characteristics of patients included in the HOVON 143 study
| Baseline characteristics . | Frail based on age (n = 13) . | Frail based on impairments (n = 32) . | Ultrafrail (n = 20) . | Total (N = 65) . |
|---|---|---|---|---|
| Age, median (range), y | 83.0 | 77.0 | 83.0 | 81.0 (70-92) |
| ≤75, n (%) | — | 6 (19) | — | 6 (9) |
| 76-80, n (%) | — | 26 (81) | — | 26 (40) |
| ≥80, n (%) | 13 (100) | — | 20 (100) | 33 (51) |
| Sex, n (%) | ||||
| Male | 7 (54) | 22 (69) | 13 (65) | 42 (65) |
| Female | 6 (46) | 10 (31) | 7 (35) | 23 (35) |
| ADL, n (%) | ||||
| >5 | 13 (100) | 24 (75) | 12 (60) | 49 (75) |
| <5 | — | 8 (25) | 8 (40) | 16 (25) |
| (I)ADL, n (%) | ||||
| >5 | 13 (100) | 9 (28) | 6 (30) | 28 (43) |
| <5 | — | 23 (72) | 14 (70) | 37 (57) |
| Charlson Comorbidity Index, n (%) | ||||
| 0-1 | 13 (100) | 9 (28) | 10 (50) | 32 (49) |
| ≥2 | — | 23 (72) | 10 (50) | 33 (51) |
| WHO status, n (%) | ||||
| 0-1 | 12 (92) | 16 (50) | 10 (56) | 38 (58) |
| ≥2 | 1 (8) | 16 (50) | 8 (44) | 25 (38) |
| Unknown | — | — | — | 2 (3) |
| IMWG frailty score, n (%) | ||||
| 2 | 13 (100) | 19 (59) | — | 32 (49) |
| 3 | — | 10 (31) | 9 (45) | 19 (29) |
| 4 | — | 3 (10) | 10 (50) | 13 (20) |
| 5 | — | — | 1 (5) | 1 (2) |
| ISS disease stage, n (%) | ||||
| I | 6 (46) | 2 (6) | 2 (10) | 10 (16) |
| II | 4 (31) | 13 (41) | 8 (40) | 25 (39) |
| III | 3 (23) | 16 (50) | 10 (50) | 29 (45) |
| Unknown | — | 1 (3) | — | 1 |
| Cytogenetic risk profile∗, n (%) | ||||
| Standard | 11 (85) | 19 (59) | 15 (75) | 45 (69) |
| High | 1 (8) | 7 (22) | 3 (15) | 11 (17) |
| Unknown | 1 (8) | 6 (19) | 2 (10) | 9 (14) |
| R-ISS disease stage (%) | ||||
| I | 1 (3) | 5 (38) | 2 (10) | 8 (12) |
| II | 21 (66) | 6 (46) | 11 (55) | 38 (58) |
| III | 6 (19) | 1 (8) | 5 (25) | 12 (18) |
| Unknown | 4 (13) | 1 (8) | 2 (10) | 7 (11) |
| Type of measurable disease, n (%) | ||||
| IgG | 2 (15) | 8 (25) | 5 (25) | 39 (60) |
| IgA | 9 (69) | 18 (56) | 12 (60) | 15 (23) |
| FLC | 2 (15) | 5 (16) | 2 (10) | 9 (14) |
| Other | — | 1 (3) | 1 (5) | 2 (3) |
| Median creatinine clearance, mL/min (range) | 52 | 52 | 36 | 56 (20-90) |
| Median hemoglobin, mmol/L, (range) | 6.5 | 6.1 | 6.1 | 6.2 (4.4-9.5) |
| Baseline characteristics . | Frail based on age (n = 13) . | Frail based on impairments (n = 32) . | Ultrafrail (n = 20) . | Total (N = 65) . |
|---|---|---|---|---|
| Age, median (range), y | 83.0 | 77.0 | 83.0 | 81.0 (70-92) |
| ≤75, n (%) | — | 6 (19) | — | 6 (9) |
| 76-80, n (%) | — | 26 (81) | — | 26 (40) |
| ≥80, n (%) | 13 (100) | — | 20 (100) | 33 (51) |
| Sex, n (%) | ||||
| Male | 7 (54) | 22 (69) | 13 (65) | 42 (65) |
| Female | 6 (46) | 10 (31) | 7 (35) | 23 (35) |
| ADL, n (%) | ||||
| >5 | 13 (100) | 24 (75) | 12 (60) | 49 (75) |
| <5 | — | 8 (25) | 8 (40) | 16 (25) |
| (I)ADL, n (%) | ||||
| >5 | 13 (100) | 9 (28) | 6 (30) | 28 (43) |
| <5 | — | 23 (72) | 14 (70) | 37 (57) |
| Charlson Comorbidity Index, n (%) | ||||
| 0-1 | 13 (100) | 9 (28) | 10 (50) | 32 (49) |
| ≥2 | — | 23 (72) | 10 (50) | 33 (51) |
| WHO status, n (%) | ||||
| 0-1 | 12 (92) | 16 (50) | 10 (56) | 38 (58) |
| ≥2 | 1 (8) | 16 (50) | 8 (44) | 25 (38) |
| Unknown | — | — | — | 2 (3) |
| IMWG frailty score, n (%) | ||||
| 2 | 13 (100) | 19 (59) | — | 32 (49) |
| 3 | — | 10 (31) | 9 (45) | 19 (29) |
| 4 | — | 3 (10) | 10 (50) | 13 (20) |
| 5 | — | — | 1 (5) | 1 (2) |
| ISS disease stage, n (%) | ||||
| I | 6 (46) | 2 (6) | 2 (10) | 10 (16) |
| II | 4 (31) | 13 (41) | 8 (40) | 25 (39) |
| III | 3 (23) | 16 (50) | 10 (50) | 29 (45) |
| Unknown | — | 1 (3) | — | 1 |
| Cytogenetic risk profile∗, n (%) | ||||
| Standard | 11 (85) | 19 (59) | 15 (75) | 45 (69) |
| High | 1 (8) | 7 (22) | 3 (15) | 11 (17) |
| Unknown | 1 (8) | 6 (19) | 2 (10) | 9 (14) |
| R-ISS disease stage (%) | ||||
| I | 1 (3) | 5 (38) | 2 (10) | 8 (12) |
| II | 21 (66) | 6 (46) | 11 (55) | 38 (58) |
| III | 6 (19) | 1 (8) | 5 (25) | 12 (18) |
| Unknown | 4 (13) | 1 (8) | 2 (10) | 7 (11) |
| Type of measurable disease, n (%) | ||||
| IgG | 2 (15) | 8 (25) | 5 (25) | 39 (60) |
| IgA | 9 (69) | 18 (56) | 12 (60) | 15 (23) |
| FLC | 2 (15) | 5 (16) | 2 (10) | 9 (14) |
| Other | — | 1 (3) | 1 (5) | 2 (3) |
| Median creatinine clearance, mL/min (range) | 52 | 52 | 36 | 56 (20-90) |
| Median hemoglobin, mmol/L, (range) | 6.5 | 6.1 | 6.1 | 6.2 (4.4-9.5) |
FLC, Free Light Chain; IgA, immunoglobulin A; IgG, immunoglobulin G; ISS, International Staging System; R-ISS, Revised International Staging System; WHO, World Health Organization.
Based on the presence of del17p, t(4;14) and/or t(14;16).